148 related articles for article (PubMed ID: 12181243)
1. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients.
Ferrandina G; Lauriola L; Zannoni GF; Fagotti A; Fanfani F; Legge F; Maggiano N; Gessi M; Mancuso S; Ranelletti FO; Scambia G
Ann Oncol; 2002 Aug; 13(8):1205-11. PubMed ID: 12181243
[TBL] [Abstract][Full Text] [Related]
2. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients.
Ferrandina G; Lauriola L; Distefano MG; Zannoni GF; Gessi M; Legge F; Maggiano N; Mancuso S; Capelli A; Scambia G; Ranelletti FO
J Clin Oncol; 2002 Feb; 20(4):973-81. PubMed ID: 11844819
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer.
Ferrandina G; Ranelletti FO; Lauriola L; Fanfani F; Legge F; Mottolese M; Nicotra MR; Natali PG; Zakut VH; Scambia G
Gynecol Oncol; 2002 May; 85(2):305-10. PubMed ID: 11972392
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase-2 (COX-2) a new prognostic and predictive factor for ovarian cancer? Are all the criteria fulfilled?
Nasi ML; Castiglione M
Ann Oncol; 2002 Aug; 13(8):1169-71. PubMed ID: 12181238
[No Abstract] [Full Text] [Related]
5. Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival.
Raspollini MR; Amunni G; Villanucci A; Boddi V; Taddei GL
Int J Gynecol Cancer; 2005; 15(2):255-60. PubMed ID: 15823108
[TBL] [Abstract][Full Text] [Related]
6. Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome.
Raspollini MR; Amunni G; Villanucci A; Boddi V; Baroni G; Taddei A; Taddei GL
Gynecol Oncol; 2004 Mar; 92(3):806-12. PubMed ID: 14984945
[TBL] [Abstract][Full Text] [Related]
7. [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications].
Wülfing C; Eltze E; Von Struensee D; Wülfing P; Bode ME; Bettendorf O; Piechota H; Hertle L
Aktuelle Urol; 2004 Aug; 35(4):331-8. PubMed ID: 15459875
[TBL] [Abstract][Full Text] [Related]
8. Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer.
Seo SS; Song YS; Kang DH; Park IA; Bang YJ; Kang SB; Lee HP
Gynecol Oncol; 2004 Mar; 92(3):927-35. PubMed ID: 14984962
[TBL] [Abstract][Full Text] [Related]
9. Prognostic role of the ratio between cyclooxygenase-2 in tumor and stroma compartments in cervical cancer.
Ferrandina G; Ranelletti FO; Legge F; Gessi M; Salutari V; Distefano MG; Lauriola L; Zannoni GF; Martinelli E; Scambia G
Clin Cancer Res; 2004 May; 10(9):3117-23. PubMed ID: 15131052
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression.
Denkert C; Weichert W; Pest S; Koch I; Licht D; Köbel M; Reles A; Sehouli J; Dietel M; Hauptmann S
Cancer Res; 2004 Jan; 64(1):189-95. PubMed ID: 14729623
[TBL] [Abstract][Full Text] [Related]
11. COX-2 status in relation to tumor microvessel density and VEGF expression: analysis in ovarian carcinoma patients with low versus high survival rates.
Raspollini MR; Amunni G; Villanucci A; Boddi V; Baroni G; Taddei A; Taddei GL
Oncol Rep; 2004 Feb; 11(2):309-13. PubMed ID: 14719060
[TBL] [Abstract][Full Text] [Related]
12. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma.
Denkert C; Köbel M; Pest S; Koch I; Berger S; Schwabe M; Siegert A; Reles A; Klosterhalfen B; Hauptmann S
Am J Pathol; 2002 Mar; 160(3):893-903. PubMed ID: 11891188
[TBL] [Abstract][Full Text] [Related]
13. Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer.
Ferrandina G; Ranelletti FO; Martinelli E; Paglia A; Zannoni GF; Scambia G
BMC Cancer; 2006 Jul; 6():182. PubMed ID: 16831230
[TBL] [Abstract][Full Text] [Related]
14. [Relationship of cyclooxygenase 2 expression and chemotherapy response and prognosis in human ovarian carcinoma].
Lou WZ; Shen K; Zhang Y; Lang JH
Zhonghua Fu Chan Ke Za Zhi; 2004 Aug; 39(8):529-32. PubMed ID: 15363351
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 expression in borderline ovarian tumors.
Ferrandina G; Zannoni GF; Ranelletti FO; Legge F; Gessi M; Salutari V; Gallotta V; Lauriola L; Scambia G
Gynecol Oncol; 2004 Oct; 95(1):46-51. PubMed ID: 15385109
[TBL] [Abstract][Full Text] [Related]
16. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.
Izquierdo MA; van der Zee AG; Vermorken JB; van der Valk P; Beliën JA; Giaccone G; Scheffer GL; Flens MJ; Pinedo HM; Kenemans P
J Natl Cancer Inst; 1995 Aug; 87(16):1230-7. PubMed ID: 7563169
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.
Chen YJ; Yuan CC; Chow KC; Wang PH; Lai CR; Yen MS; Wang LS
Gynecol Oncol; 2005 Apr; 97(1):110-7. PubMed ID: 15790446
[TBL] [Abstract][Full Text] [Related]
18. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
Davidson B; Holth A; Hellesylt E; Tan TZ; Huang RY; Tropé C; Nesland JM; Thiery JP
Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
[TBL] [Abstract][Full Text] [Related]
19. Glutathione S-transferase activity in epithelial ovarian cancer: association with response to chemotherapy and disease outcome.
Ferrandina G; Scambia G; Damia G; Tagliabue G; Fagotti A; Benedetti Panici P; Mangioni C; Mancuso S; D'Incalci M
Ann Oncol; 1997 Apr; 8(4):343-50. PubMed ID: 9209663
[TBL] [Abstract][Full Text] [Related]
20. Concomitant radiochemotherapy plus surgery in locally advanced cervical cancer: update of clinical outcome and cyclooxygenase-2 as predictor of treatment susceptibility.
Distefano M; Ferrandina G; Smaniotto D; Margariti AP; Zannoni G; Macchia G; Manfredi R; Mangiacotti MG; Cellini N; Scambia G
Oncology; 2004; 67(2):103-11. PubMed ID: 15539913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
